852A
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms
Conditions
Neoplasms
Trial Timeline
Oct 1, 2003 → Jan 1, 2006
NCT ID
NCT00095160About 852A
852A is a phase 1 stage product being developed by Pfizer for Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00095160. Target conditions include Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00319748 | Phase 2 | Completed |
| NCT00276159 | Phase 2 | Terminated |
| NCT00189332 | Phase 2 | Completed |
| NCT00091689 | Phase 1 | Completed |
| NCT00095160 | Phase 1 | Completed |
Competing Products
20 competing products in Neoplasms